Recent events
Recent events tied to this brand in public sources.
Back to profile29 entries · Page 1 of 2
2026
Astorg completes acquisition of Thermo Fisher Scientific's microbiology business
Astorg, a pan-European private equity firm, announced the completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business now operates as an independent company led by CEO Dirk Bontridder and plans to launch under a new corporate brand later in 2026.
2022
Thermo Fisher announces agreement to acquire The Binding Site Group
Thermo Fisher announced a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital in an all-cash transaction valued at £2.25 billion, or $2.6 billion. Completion was expected in the first half of 2023, subject to customary closing conditions, including regulatory approvals.
2022
Bio-Techne and Thermo Fisher agree to develop and commercialize ExoTRU
Bio-Techne announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize ExoTRU, a kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.
2022
Olaris and Thermo Fisher partner to evaluate transplant diagnostic
Olaris announced a partnership with Thermo Fisher Scientific to evaluate a metabolomics-based diagnostic for assessing kidney transplant recipients’ risk of complications from overimmunosuppression.
2021
Lacks estate sues Thermo Fisher Scientific over HeLa cells
The estate of Henrietta Lacks sued Thermo Fisher Scientific, alleging that the company continued commercializing results derived from HeLa cells taken without Lacks' knowledge or consent. The lawsuit seeks the company's net profits from commercialization and an injunction against use of the cells without the estate's permission; the allegations are not presented as a court finding.
2021
FDA approves Oncomine Dx Target Test as a companion diagnostic for EXKIVITY
The FDA granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to identify eligible patients for Takeda’s EXKIVITY therapy.
2021
Nanoscience Instruments announces Axia ChemiSEM launch
Nanoscience Instruments announced the launch of the Axia ChemiSEM, a floor-model scanning electron microscope from Thermo Fisher Scientific.
2021
Thermo Fisher updates TaqMan mutation panel to detect Delta and Lambda
Thermo Fisher Scientific announced an update to its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains.
2021
Ortho Clinical Diagnostics and Thermo Fisher Scientific announce distribution agreement
Ortho Clinical Diagnostics announced a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions for VITROS System customers worldwide, with China noted as in development.
2021
Moderna enters vaccine manufacturing agreement with Thermo Fisher
Moderna said it entered into an agreement with Thermo Fisher Scientific for manufacturing and packaging its Covid-19 vaccine. Thermo Fisher's Greenville, North Carolina site will provide fill/finish manufacturing services and packaging for hundreds of millions of doses.
2021
PROGEN signed a distribution agreement with Thermo Fisher Scientific
PROGEN signed a non-exclusive distribution agreement with Thermo Fisher Scientific for selected proprietary antibodies. Thermo Fisher will offer 371 of PROGEN's primary antibodies globally.
2021
Thermo Fisher enters collaboration agreement with University of Missouri
The University of Missouri and Thermo Fisher Scientific entered a collaboration agreement under which new Thermo Fisher equipment will be placed in the Electron Microscopy Core Facility of the NextGen Precision Health building opening that fall. The agreement also includes a significant in-kind contribution from Thermo Fisher.
2021
WuXi Diagnostic completes $150 million Series B financing
WuXi Diagnostic announced that it completed a $150 million Series B financing.
2021
WuXi Diagnostics completes US$150 million Series B financing
WuXi Diagnostics announced that it completed US$150 million in Series B funding, joined by new investors including Thermo Fisher, Shiyu Capital, ABC International, Sunland Capital and CCBI Tech Venture, alongside existing shareholder YF Capital.
2021
Juventas and Thermo Fisher announce a licensing partnership
Juventas announced a strategic cooperation with Thermo Fisher under which Juventas will receive non-exclusive commercial-use rights to Gibco CTS Dynabeads CD3/CD28 for clinical development and commercial production of CAR-T therapies in China.
2021
Thermo Fisher acquires Mesa Biotech
Thermo Fisher acquired Mesa Biotech for $550 million, according to the report.
2020
Thermo Fisher Scientific launches SARS-CoV-2 antibody test portfolio
Thermo Fisher Scientific launched a portfolio of SARS-CoV-2 antibody tests, including the OmniPATH COVID-19 Total Antibody ELISA test and the EliA SARS-CoV-2-Sp1 IgG test.
2020
Humanigen announces manufacturing collaboration with Thermo Fisher Scientific
Humanigen announced a strategic collaboration with Thermo Fisher Scientific to expand manufacturing capacity for lenzilumab in support of a potential Emergency Use Authorization.
2020
Thermo Fisher announces laboratory plastics production expansion
Thermo Fisher Scientific announced an investment of more than $140 million to expand laboratory plastics consumables production, supporting demand for COVID-19 testing and the development and manufacture of therapies and vaccines. The company also said it was expanding sites in the United States, Mexico and Finland.
2020
INOVIO and Thermo Fisher sign vaccine manufacturing letter of intent
INOVIO announced that Thermo Fisher Scientific had signed a letter of intent to manufacture INOVIO's INO-4800 COVID-19 vaccine candidate, including drug-substance production and fill-and-finish work at US facilities.